Journal article
Interruptions in bladder cancer care during the COVID-19 public health emergency
Urologic oncology, Vol.42(4), pp.116.e17-116.e21
04/2024
DOI: 10.1016/j.urolonc.2023.11.010
PMID: 38087711
Abstract
Academic and community urology centers participating in a pragmatic clinical trial in non-muscle-invasive bladder cancer completed monthly surveys assessing restrictions in aspects of bladder cancer care due to the COVID-19 Public Health Emergency. Our objective was to describe pandemic-related restrictions on bladder cancer care.
We invited 32 sites participating in a multicenter pragmatic bladder cancer trial to complete monthly surveys distributed through REDCap beginning in May 2020. These surveys queried sites on whether they were experiencing restrictions in the use of elective surgery, transurethral resection of bladder tumors (TURBT), radical cystectomy, office cystoscopy, and intravesical bacillus Calmette-Guerin (BCG) availability. Responses were collated with descriptive statistics.
Of 32 eligible sites, 21 sites had at least a 50% monthly response rate over the study period and were included in the analysis. Elective surgery was paused at 76% of sites in May 2020, 48% of sites in January 2021, and 52% of sites in January 2022. Over those same periods, coinciding with COVID-19 incidence waves, TURBT was restricted at 10%, 14%, and 14% of sites, respectively, radical cystectomy was restricted at 10%, 14%, and 19% of sites, respectively, and cystoscopy was restricted at 33%, 0%, and 10% of sites, respectively.
Bladder cancer care was minimally restricted compared with more pronounced restrictions seen in general elective surgeries during the COVID-19 pandemic.
Details
- Title: Subtitle
- Interruptions in bladder cancer care during the COVID-19 public health emergency
- Creators
- John L Gore - University of WashingtonKristin Follmer - University of WashingtonJason Reynolds - University of WashingtonMichael Nash - University of WashingtonChristopher B Anderson - Columbia University Irving Medical CenterJames W F Catto - Department of Urology, Sheffield Teaching Hospitals NHS (National Health Service) Foundation Trust, Sheffield, United KingdomKarim Chamie - David Geffen School of Medicine at UCLASiamak Daneshmand - Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CARian DicksteinTullika Garg - Penn State Milton S. Hershey Medical CenterScott M Gilbert - Moffitt Cancer CenterThomas J Guzzo - University of PennsylvaniaAshish M Kamat - The University of Texas MD Anderson Cancer CenterMax R KatesBrian R Lane - Spectrum HealthYair Lotan - The University of Texas Southwestern Medical CenterAhmed M Mansour - Department of Urology, University of Texas Health, San Antonio, TXViraj A Master - Emory UniversityJeffrey S Montgomery - Michigan MedicineDavid S Morris - Urology AssociatesKenneth G Nepple - University of IowaBrock B O'Neil - University of UtahSanjay Patel - University of OklahomaKamal Pohar - The Ohio State UniversitySima P Porten - University of California - San Francisco School of MedicineStephen B Riggs - Levine Cancer InstituteAlexander Sankin - Montefiore Medical CenterKristen R Scarpato - Vanderbilt University Medical CenterNeal D Shore - Carolina Urologic Research CenterGary D Steinberg - Rush University Medical CenterSeth A Strope - Urology of St. Louis, St. Louis, MOJennifer M Taylor - Baylor College of MedicineBryan A Comstock - University of WashingtonLarry G Kessler - University of WashingtonErika M Wolff - University of WashingtonAngela B Smith - University of North Carolina at Chapel Hill
- Resource Type
- Journal article
- Publication Details
- Urologic oncology, Vol.42(4), pp.116.e17-116.e21
- DOI
- 10.1016/j.urolonc.2023.11.010
- PMID
- 38087711
- eISSN
- 1873-2496
- Grant note
- DOI: 10.13039/100006093, name: Patient-Centered Outcomes Research Institute
- Language
- English
- Electronic publication date
- 12/11/2023
- Date published
- 04/2024
- Academic Unit
- Urology
- Record Identifier
- 9984530273402771
Metrics
5 Record Views